[go: up one dir, main page]

WO2000008018A1 - Derives de benzothiepine, leur procede de preparation et leurs utilisations - Google Patents

Derives de benzothiepine, leur procede de preparation et leurs utilisations Download PDF

Info

Publication number
WO2000008018A1
WO2000008018A1 PCT/JP1999/004269 JP9904269W WO0008018A1 WO 2000008018 A1 WO2000008018 A1 WO 2000008018A1 JP 9904269 W JP9904269 W JP 9904269W WO 0008018 A1 WO0008018 A1 WO 0008018A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituent
compound
aromatic heterocyclic
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1999/004269
Other languages
English (en)
Japanese (ja)
Inventor
Tsuneo Yasuma
Haruhiko Makino
Akira Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to AU51949/99A priority Critical patent/AU5194999A/en
Priority to EP99936994A priority patent/EP1103552A4/fr
Priority to US09/744,857 priority patent/US6355672B1/en
Priority to CA002339662A priority patent/CA2339662A1/fr
Publication of WO2000008018A1 publication Critical patent/WO2000008018A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to a benzochepine derivative having a bone formation promoting action and a cartilage formation promoting action, a method for producing the same, and a pharmaceutical composition containing the same as an active ingredient.
  • Bone disease is a pathological condition or disease in which the loss of bone has increased to some extent, thereby causing some symptoms or danger.
  • the main symptoms of osteoporosis, a bone disease are kyphosis of the spine, fractures of the lumbar spine and the vertebral body, femoral neck, lower radius, ribs, upper humerus, and the like.
  • bone tissue bone formation and bone destruction due to bone resorption are constantly repeated while maintaining a balance.
  • Osteoblasts play a central role in bone formation
  • osteoclasts play a central role in bone resorption.
  • bone resorption inhibiting substances such as estrogens, calcitonin, and bisphosphonates have been mainly used as preventive and therapeutic drugs for osteoporosis.
  • the administration target is limited or the effect may be uncertain, and a sufficient effect has not been obtained.
  • the present inventors have synthesized various benzocepin derivatives, and have studied their biological activity and pharmacological properties. Diligent study on the chemical behavior, the formula in the second position of the skeleton
  • R 1 represents a non-aromatic heterocyclic group which may have a substituent
  • R 2 represents a hydrogen atom or a hydrocarbon group which may have a substituent. It has been found that a compound having a group represented by the formula (1) has excellent bone formation promoting action and cartilage formation promoting action, and is excellent in oral absorbability. The present inventors have further studied based on these findings and completed the present invention.
  • the present invention provides a method of formula (1)
  • ring A is a benzene ring which may have a substituent
  • R 1 is a non-aromatic heterocyclic group which may have a substituent
  • R 2 and R 3 are each a hydrogen atom or A hydrocarbon group which may have a substituent
  • n is an integer of 0 to 3
  • Ring A is a halogen atom, a hydroxy group, (: .alkyl group, C ⁇ ].
  • Alkoxy group, formula: —O— (CH 2 ) m—O— (where m is 1 to 4 alkylenedioxy O dimethylvinylsiloxy groups and C Bok in an integer) are i Table i. was 1 or selected from alkylthio radical is a two benzene ring which may be substituted with a substituent, R 2 and R 3 Is a hydrogen atom, a C 6 alkyl group or a phenyl group, respectively.
  • Ring A is represented by the formula [Wherein, R 4 and R 5 are each a hydrogen atom or. It may represent an alkyl group or R 4 and R 5 may together form a 4- alkylene chain. ]
  • R 2 and R 3 are each a hydrogen atom or a dialkyl group;
  • the non-aromatic heterocyclic group which may have a substituent represented by R 1
  • the non-aromatic heterocyclic group is a hetero atom selected from a nitrogen atom, a sulfur atom and an oxygen atom.
  • the 5- or 6-membered non-aromatic heterocyclic group in the 5- or 6-membered non-aromatic heterocyclic group is pyrrolidine, imidazolidine, thiazolidine, isothiazolidine, oxazolidine, oxasaziazolidine, piperidine, piperazine
  • the substituent in the optionally substituted non-aromatic heterocyclic group represented by R 1 is 1 to 3 halogen atoms, hydroxy or oxo.
  • the compound according to the above (1) which is alkyl, alkoxy, 6- acyl, amino, mono- or di-C-e-alkylamino, C ⁇ 6- alkylsulfonyl, carboxy or C-ealkoxy-carbonyl,
  • R 2 is a hydrogen atom
  • R 3 is 3 alkyl group
  • the compound of the above (3) above wherein forming the turned R 4 and R 5 gar cord ( ⁇ _ 2 alkylene chain
  • R 2 and R 3 are each a hydrogen atom, the compound of the above (3) above, wherein R 4 and R 5 are each Ji Bok 3 alkyl group,
  • ring A represents a benzene ring which may have a substituent
  • R 1 represents a non-aromatic heterocyclic group which may have a substituent
  • R 2 represents a hydrogen atom or a substituent
  • R 31 represents a hydrocarbon group which may have a substituent
  • n represents an integer of 0 to 3.
  • ring A represents a benzene ring which may have a substituent
  • R 3 represents a hydrogen atom or a hydrocarbon group which may have a substituent.
  • R 1 represents a non-aromatic heterocyclic group which may have a substituent
  • R 2 represents a hydrogen atom or a hydrocarbon group which may have a substituent
  • n represents 0 to An integer of 3 is shown.
  • R 11 is pyrrolidinyl, dioxopyrrolidinyl, piberidinyl, mono or dioxopiperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, dioxothiazolidinyl, dioxoimidazolidinyl, 1 Monomethyl-dioxomidazolidinyl, dioxoxazolidinyl, dioxotetrahydroisothiazolidinyl, mono- or dioxoxazolidinyl or dioxoxaziazolidinyl. ] Or a salt thereof,
  • ring A is a benzene ring which may have a substituent
  • R 1 is a non-aromatic heterocyclic group which may have a substituent
  • R 2 and R 3 are each a hydrogen atom or A hydrocarbon group which may have a substituent
  • n is an integer of 0 to 3
  • a pharmaceutical composition comprising the compound (I) or a salt thereof represented by the formula:
  • examples of the substituent on the optionally substituted benzene ring represented by ring A include a halogen atom, a hydroxy group, a nitro group, an optionally substituted alkyl group, and a substituted An optionally substituted hydroxy group, an optionally substituted mercapto group, an optionally substituted amino group, an acyl group, a mono- or dialkoxyphosphoryl group, a phosphono group, an optionally substituted aryl group, An optionally substituted aralkyl group or an optionally substituted aromatic heterocyclic group is used, and these substituents are the same or different, and 1 to 4, preferably 1 or 2, are substituted on the benzene ring. May be.
  • halogen atom for example, fluorine, chlorine, bromine, iodine and the like are used.
  • the alkyl group in the “optionally substituted alkyl group” is preferably an alkyl group having 1 to 10 carbon atoms (eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl). Butyl, 'pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl or decyl, etc.) and cycloalkyl groups having 3 to 7 carbon atoms (eg, cyclopropyl, cyclobutyl, cyclobutyl) Hexyl or cycloheptyl, etc.
  • 1 to 10 carbon atoms eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl.
  • octogen atoms eg, fluorine, chlorine, bromine, iodine, etc.
  • hydroxyl groups alkoxy groups having 1 to 6 carbon atoms (eg, methoxy, ethoxy, etc.).
  • alkoxy groups having 1 to 6 carbon atoms eg, methoxy, ethoxy, etc.
  • Mono- or di- (alkoxy having 1 to 6 carbon atoms) phosphoryl group for example, methoxyphosphoryl, ethoxyphosphoryl, dimethoxyphosphoryl, ethoxyphosphoryl, etc.
  • phosphono group Up to three may be substituted.
  • substituted alkyl group examples include, for example, trifluoromethyl, trifluorethyl, trichloromethyl, hydroxymethyl, 2-hydroxyethyl, methoxyethyl, 1-methoxyethyl, 2-methoxyethyl, 2,2-jetoxethyl, Examples include diethoxyphosphorylethyl, phosphono groups, and phosphonomethyl.
  • substituted hydroxyl group in the "optionally substituted hydroxyl group” for example, an alkoxy group, an alkenyloxy group, an aralkyloxy group, an acyloxy group, an aryloxy group and the like are used.
  • the “alkoxy group” is preferably an alkoxy group having 1 to 10 carbon atoms (eg, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, heptyloxy or nonyloxy) and carbon.
  • Cycloalkoxy groups of the formulas 4 to 6 eg, cyclobutoxy, cyclopentoxy or cyclohexyloxy
  • alkenyloxy group is preferably an alkenyloxy group having 2 to 10 carbon atoms, for example, aryloxy, crotyloxy, 2-pentenyloxy, 3-hexenyloxy, 2-cyclopentenylmethoxy or 2-cyclohexenylmethoxy. Is used.
  • the "aralkyloxy group” is preferably an aralkyloxy group having 6 to 19 carbon atoms, more preferably an aralkyloxy group having 6 to 14 carbon atoms and 1 to 4 carbon atoms (eg, benzyloxy, phenethyloxy) Etc.) are used.
  • an alkanoyloxy group for example, an alkanoyloxy group having 2 to 10 carbon atoms (eg, acetyloxy, propionyloxy, n-butyryloxy, hexanoyloxy, etc.) is preferably used.
  • the “aryloxy group” is preferably an aryloxy group having 6 to 14 carbon atoms (eg, phenoxy, Biphenyloxy) is used. These groups are further substituted with, for example, one to three halogen atoms, a hydroxyl group, an alkoxy group having 1 to 6 carbon atoms, a mono- or di- (alkoxy having 1 to 6 carbon atoms) phosphoryl group, and the like.
  • further substituted hydroxyl groups include, for example, trifluoromethoxy, 2,2,2-trifluoroethoxy, difluoromethoxy, 2-methoxyethoxy, 4-chlorobenzyloxy, 2 — (3,4-dimethoxyphenyl) ethoxy and the like.
  • alkylthio group for example, an alkylthio group, an aralkylthio group, an acylthio group and the like are used.
  • the “alkylthio group” is preferably an alkylthio group having 1 to 10 carbon atoms (eg, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, nonylthio, etc.) and a cycloalkyl group having 4 to 6 carbon atoms.
  • aralkylthio group is preferably an aralkylthio group having 7 to 19 carbon atoms, more preferably an aralkylthio group having 6 to 14 carbon atoms-an alkylthio group having 1 to 4 carbon atoms, such as benzylthio or phenethylthio. .
  • an alkanoylthio group for example, an alkanoylthio group having 2 to 10 carbon atoms (eg, acetylthio, propionylthio, n-butylylthio, hexanoylthio, etc.) is used. These groups may be further substituted with 1 to 3 halogen atoms, hydroxyl groups, alkoxy groups having 1 to 6 carbon atoms, mono- or di- (alkoxy having 1 to 6 carbon atoms) phosphoryl groups, and the like. Good.
  • substituted thiol group examples include, for example, trifluoromethylthio, 2,2,2-trifluoroethylthio, 2-methoxyethylthio, 4-cyclobenzoylthio, and 3,4-dichlorobenzylthio. , 4-fluorobenzylthio, 2- (3,4-dimethoxyphenyl) ethylthio and the like.
  • substituent of the substituted amino group in the “optionally substituted amino group” include the aforementioned alkyl group having 1 to 10 carbon atoms and alkenyl group having 2 to 10 carbon atoms (eg, aryl , Vinyl, 2-pentene-1 f, 3-pentene-1-yl, 2-hexene-1 -yl, 3-hexene-1 -yl, 2-cyclohexenyl, 2-cy Clopentenyl, 2-methyl-2-propene-11-yl, 3-methyl_2-buten-1-yl, etc.), aryl group having 6 to 14 carbon atoms or aralkyl having 7 to 19 carbon atoms
  • substituents may be the aforementioned halogen atom, an alkoxy group having 1 to 6 carbon atoms, a monol or di (alkoxy having 1 to 6 carbon atoms) phosphoryl group, a phosphono group.
  • substituted amino group include, for example, methylamino, dimethylamino, ethylamino, acetylamino, dibutylamino, diarylamino, cyclohexylamino, phenylamino or N-methyl-N-phenylamino, N-methyl-N- (4-chlorobenzyl).
  • acyl group an organic carboxylate group or a sulfonate group having a hydrocarbon group having 1 to 6 carbon atoms (eg, methyl, ethyl, ⁇ -propyl, hexyl, phenyl, etc.) is used.
  • organic carboxylate acryl group examples include formyl, an alkyl monofunctional ruponyl group having 1 to 10 carbon atoms (eg, acetyl, propionyl, butyryl, valeryl, bivaloyl, hexanoyl, octanoyl, cyclobutane propylonyl) , Cyclohexane carbonyl, cycloheptane carbonyl, etc.), alkenyl-carbonyl group having 2 to 10 carbon atoms (eg, crotonyl, 2-cyclohexene carbonyl, etc.), aryl carbonyl group having 6 to 14 carbon atoms Group (eg, benzoyl, etc.), aralkyl monocarbonyl group having 7 to 19 carbon atoms (eg, benzylcarbonyl, benzhydrylcarbonyl, etc.), 5- or 6-membered aromatic heterocyclic carbonyl group (eg,
  • sulfonate sulfonate having a hydrocarbon group having 1 to 6 carbon atoms for example, methanesulfonyl, ethanesulfonyl and the like are used. These groups may be further substituted with 1 to 3 substituents, for example, the above-mentioned octylogen atom, hydroxyl group, alkoxy group having 1 to 6 carbon atoms, amino group and the like.
  • acyl group examples include, for example, trifluoroacetyl, trichloroacetyl, 4-methoxybutyryl, 3-cyclohexyloxypropionyl, 4-chlorobenzoyl, and 3,4'-dimethoxybenzoyl.
  • the "mono- or di-alkoxyphosphoryl group” includes, for example, a mono-alkoxyphosphoryl group such as methoxyphosphoryl, ethoxyphosphoryl, propoxyphosphoryl, isopropoxyphosphoryl, .butoxyphosphoryl, pentyloxyphosphoryl, hexyloxyphosphoryl, etc.
  • di C _ 6 alkoxy phosphoryl groups hexyl O carboxymethyl phosphonate drills, etc., to di is used.
  • _ 6 alkoxy group for example, dimethoxyphosphoryl, diethoxyphosphoryl, dipropionate Pokishihosuhoriru, diisopropoxy phosphoryl, ethylene O carboxymethyl phosphoryl, dibutoxyethoxyethyl Shiho Suho drill or the like is used.
  • an aryl group having 6 to 14 carbon atoms for example, phenyl, naphthyl, anthryl and the like are preferably used. It may be substituted with 1 to 3 alkyl groups of 1 to 10 atoms, a halogen atom, a hydroxyl group, an alkoxy group of 1 to 6 carbon atoms and the like.
  • Specific examples of the substituted aryl group include, for example, 4-chlorophenyl, 3,4-dimethoxyphenyl, 4-cyclohexylphenyl, 5,6,7,8-tetrahydro-2-naphthyl and the like.
  • aralkyl group in the “optionally substituted aralkyl group” is it preferably a carbon number?
  • An aralkyl group having 1 to 19 carbon atoms for example, benzyl, naphthylethyl, trityl, etc., is used. May be substituted with one to three.
  • Specific examples of the substituted aralkyl group include, for example, 4-chlorobenzyl, 3,4-dimethoxybenzyl, 4-cyclohexylbenzyl, 5,6,7,8-tetrahydro-2-naphthylethyl and the like.
  • the aromatic heterocyclic group in the “optionally substituted aromatic heterocyclic group” is preferably a 5- to 6-membered aromatic heterocyclic group having 1 to 4 nitrogen, oxygen or Z and sulfur atoms.
  • furyl, chenyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl and the like are used, and these groups are those having 1 to 10 carbon atoms as described above. It may be substituted with 1 to 3 alkyl groups, halogen atoms, hydroxyl groups, alkoxy having 1 to 6 carbon atoms, and the like.
  • Preferred substituents on ring A include, for example, halogen atom, and Alkyl group, i.
  • the non-aromatic heterocyclic ring in the non-aromatic heterocyclic group which may have a substituent represented by R 1 is a heteroatom selected from a nitrogen atom, a sulfur atom and an oxygen atom And a 3- to 8-membered non-aromatic heterocycle containing 1 to 4 of the following.
  • Examples include oxylane, azetidine, oxetane, chetan, pyrrolidine, tetrahydrofurin, thiolan, piperidine, tetrahydropyran, morpholine, thiomorpholine, piperazine, homopiridin, pyrroline, imidazolidine, thiazoline, and isothiazoline.
  • a 4- to 7-membered non-aromatic heterocyclic ring is preferable, and a 5- to 6-membered non-aromatic heterocyclic ring is particularly preferable.
  • examples of the substituent in the optionally substituted non-aromatic heterocyclic group include (i) a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), (ii) hydroxy or Oxo, ( ⁇ ⁇ ) alkoxy group having 1 to 6 carbon atoms (eg, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, etc.), 3 2
  • a halogen atom eg, fluorine, chlorine, bromine, iodine, etc.
  • hydroxy or Oxo hydroxy or Oxo
  • alkoxy group having 1 to 6 carbon atoms eg, methoxy, ethoxy, propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, etc.
  • alkyl group having 1 to 6 carbon atoms eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, ten-butyl, pentyl, isopentyl, neopentyl, hexyl, etc.
  • Amino group eg, amino, methylamino, ethylamino, dimethylamino, acetylamino, dipropylamino, etc.
  • amino group substituted with an acyl group eg, alkanoyl group having 1 to 10 carbon atoms, etc.
  • acyl group eg, alkanoyl group having 1 to 10 carbon atoms, etc.
  • acetylamino, propionylamino, benzoylamino, etc. a carbamoyl group which may be substituted with an alkyl group having 1 to 6 carbon atoms (eg, carbamo
  • substituents examples include a halogen atom, hydroxy or oxo, and L.
  • substituents which may have three substituents include, for example, oxilanyl, azetidinyl, oxetanyl, cesinyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperidyl , Tetrahydroviranyl, morpholinyl, thiomorpholinyl, piperazinyl, homopiperidyl, 4-oxopiperidyl, piperolinyl, imidazolidinyl, 4-form
  • non-aromatic heterocyclic groups include a benzene ring, a 6-membered ring containing 2 or less nitrogen atoms or one May be condensed with a 5-membered ring containing a sulfur atom.
  • fused non-aromatic heterocyclic group include, for example, chromanyl, isochromanyl, indolinyl, isoindolinyl, thiochromanyl, isothiochromanyl and the like.
  • non-aromatic heterocyclic ring in the non-aromatic heterocyclic group which may have a substituent is a 5- to 6-membered non-aromatic heterocyclic ring containing at least one nitrogen atom, 5- to 6-membered non-aromatic heterocycles containing one nitrogen atom and one sulfur or oxygen atom are included.
  • Preferred as the 5- to 6-membered non-aromatic heterocyclic ring containing at least one nitrogen atom include, for example, pyrrolidine, imidazolidine, thiazolidine, isothiazolidine, oxazolidine, oxaziazolidine, piperidine, Piperazine, thiomorpholine, and morpholine.
  • Preferred examples of the 5- to 6-membered non-aromatic ring containing one nitrogen atom and one sulfur atom or oxygen atom include thiazolidine, oxazolidine, thiomorpholine, morpholine and the like.
  • R 2 R 3 in the above formula, represented by R 3 1, and as the hydrocarbon group in the "optionally substituted hydrocarbon group" represented by R 2 1 below, to have the same Alkyl groups (preferably alkyl groups having 1 to 10 carbon atoms), alkenyl groups (preferably alkenyl groups having 2 to 10 carbon atoms), aryl groups (preferably aryl groups having 6 to 14 carbon atoms) ), An aralkyl group (preferably an aralkyl having from 1 to 19 carbon atoms) and the like.
  • the substituent on the hydrocarbon group the above-mentioned halogen atom, dialkyl- 6 alkoxyphosphoryl group, phosphono group and the like are used.
  • hydrocarbon group in the above-mentioned “optionally substituted hydrocarbon group” examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, and the like.
  • a straight-chain or branched 6- alkyl group such as xyl is preferred. Of these, C 4 alkyl groups are preferred.
  • R 2 , R 3 , R 21 and R 31 are particularly preferably unsubstituted hydrocarbon groups.
  • R 4 and R 5 are respectively shown.
  • the alkyl group include Examples include straight-chain or branched alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, and hexyl. Among them, an alkyl group is preferable, and an alkyl group is particularly preferable.
  • C _ 4 alkylene chain such connexion formed R 4 and R 5 gar cord for example, methylene, ethylene, Bok Rimechiren, tetramethylene and the like.
  • n represents an integer of 0 to 3, and particularly preferably 1 or 2.
  • R 11 is dioxopyrrolidinyl, mono- or dioxopiperidinyl, thiomorpholinyl, thiazolidinyl, dioxothiazolidinyl, 1-methyl-oxoimidazolinyl, dioxoo Xazozolinyl, dioxotetrahydroisothiazolinyl, dioxooxadiazazolidinyl, etc., among which 2,5-dioxopyrrolidinyl, 4-oxopiperidinyl, 2,6 —Dioxopiperidinyl, thiomorpholinyl, thiazolidinyl, 2,4-dioxothiazolidinyl, 1-methyl— 2,4-dioxoimidazolinyl, 2,4-dioxoxazolidinyl Preferred is 1,1,1-dioxotetrahydro-2H-isothiazolinyl or 2,4
  • the compound of the formula (1) of the present invention is represented by the formula 2 ) n— K
  • (2R, 4S) -coordinated optically active forms are preferred. Further, it is preferable that the compound does not substantially contain a (2S, 4R) coordinated compound and has an optical purity close to 100%.
  • the compound (I) of the present invention comprises a compound represented by the formula (II) (including its optically active substance), a reactive derivative at the carboxyl group or a salt thereof as shown in the following reaction formula:
  • Suitable reactive derivatives of the compound represented by the formula (II) (including its optically active form) at the lipoxyl group include: acid halides (eg, acid chlorides, etc.); acid azides; acid anhydrides [eg Substituted phosphoric acids such as dialkyl phosphoric acid, phenyl phosphoric acid, diphenyl phosphoric acid, dibenzyl phosphoric acid, halogenated phosphoric acid, dialkyl phosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid such as methanesulfonic acid, for example, acetic acid, propion Acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, mixed acid with aliphatic carboxylic acid such as trichloroacetic acid or acid such as aromatic carboxylic acid such as benzoic acid; symmetrical acid anhydride Activated amides [eg, imi
  • Suitable salts of the reactive derivative of the compound represented by the formula (II) include, for example, alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, ammonium salt, and the like.
  • Base salts such as trimetylamine salts, triethylamine salts, pyridine salts, picoline salts, dicyclohexylamine salts, and organic base salts such as ⁇ , ⁇ -dibenzylethylenediamine salt.
  • Suitable reactive derivatives at the amino group of the compound of formula (III) include, for example, Schiff bases formed by the reaction of a compound of formula (III) with a carbonyl, ketone, etc.
  • Type imino or its enamine type tautomer a compound represented by the formula ( ⁇ ⁇ )
  • Trimethylsilyl A silyl derivative formed by a reaction with a silyl compound such as acetoamide, mono (trimethylsilyl) acetamide, bis (trimethylsilyl) urea; a compound represented by the formula (in) and phosphorus trichloride or phosgene; And the like.
  • the reaction of the present invention represented by the above [Formula 1] includes alcohols (eg, methanol, ethanol, ⁇ -propanol, isopropanol, ⁇ -butanol, 3-pentanol, etc.), aromatic hydrocarbons (eg, , Benzene, toluene, xylene, etc.), halogenated hydrocarbons (eg, carbon tetrachloride, 1,2-dichloroethane, dichloromethane, chloroform, monochloromethane, ethylene chloride, etc.), saturated hydrocarbons (eg, to Xane, heptane, cyclohexane, etc.), ethers (eg, getyl ether, Tetrahydrofuran, dioxane, dimethoxyethane, isopropyl ether, etc.), ketones (eg, acetone, methyl ethyl ketone, etc.), nitriles (e
  • water for example, alcohols such as methanol and ethanol, acetone, dioxane, acetonitrile, chloroform, dichloromethane, ethylene chloride, tetrahydrofuran, ethyl acetate, N, N-dimethylformamide, and common pyridines such as pyridine It is preferably carried out in a solvent.
  • N N'-dicyclohexylcarpoimide; N-cyclohexyl N '—Morpholinoethyl carpoimide; N-cyclohexyl ⁇ ' — (4-Jetylaminocyclohexyl) carpoimide; ⁇ , N '—Jetyl carpoimide,,, N' —Diiso Propylcarpoimidide, ⁇ -ethyl- ⁇ '-(3-dimethylaminopropyl) carbopimidide; ⁇ , N'-carbonylbis (2-methylimidazole); pentamethyleneketene- ⁇ -hexylimine imine; diphenylketen 1-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl
  • This reaction can also be performed using alkali metal bicarbonate (eg, sodium bicarbonate), tri (C- 4 ) alkylamine (eg, trimethylamine), pyridine, N— (Ci- 4 ) -alkylmorpholine (eg, , N- methylmorpholine), ⁇ , ⁇ - di (C! _ 4) alkyl benzyl ⁇ Min (New, may be carried out in the presence of Nyu- dimethyl pen Jill ⁇ Min) or the like of an inorganic or organic base.
  • alkali metal bicarbonate eg, sodium bicarbonate
  • tri (C- 4 ) alkylamine eg, trimethylamine
  • pyridine N— (Ci- 4 ) -alkylmorpholine (eg, , N- methylmorpholine)
  • ⁇ , ⁇ - di (C! _ 4) alkyl benzyl ⁇ Min New, may be carried out in the presence of Nyu- dimethyl pen Jill
  • the reaction temperature is not particularly limited, but the reaction is usually carried out under cooling or heating (about 110 to 120 ° C, preferably about 15 to 50 ° C).
  • the reaction time is generally about 0.5 hour to about 100 hours, preferably about 1 hour to about 50 hours.
  • the compound (I) or a salt thereof thus obtained can be isolated and purified by known separation and purification means such as concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like. .
  • the compound represented by the formula (II) or a reactive derivative thereof at the carboxy group can be prepared by a method known per se, for example, JP-A-08-231569 It can be produced by the method disclosed in the gazette or a method analogous thereto.
  • the compound in which n is 1 and the non-aromatic heterocyclic group represented by R 1 has a bond at a nitrogen atom can be obtained by the method shown in the following reaction formula or a method similar thereto. It can be produced by a method, a method described in Reference Examples described later, or a method analogous thereto. 0 2- ⁇ v //-(CH 2 ) n — X 1st step HR 11
  • a 4-nitrophenylalkyl halide and a non-aromatic heterocyclic ring which may have a substituent (represented by HR 11.
  • R 11 is a non-aromatic heterocyclic ring having a bond at a nitrogen atom. Represents an aromatic heterocyclic group) in an appropriate solvent in the presence of a base.
  • the 4-phenyl phenyl halide include 4-nitrobenzyl chloride.
  • the base include, for example, inorganic bases such as sodium hydride and potassium carbonate, triethylamine, pyridine, 1,8-diazabicyclo
  • the solvent examples include ketones (eg, acetone, methyl ethyl ketone, etc.), nitriles (eg, acetoniryl), ethers (eg, tetrahydrofuran), esters (eg, ethyl acetate), amides (Eg, ⁇ , ⁇ -dimethylformamide).
  • ketones eg, acetone, methyl ethyl ketone, etc.
  • nitriles eg, acetoniryl
  • ethers eg, tetrahydrofuran
  • esters eg, ethyl acetate
  • amides Eg, ⁇ , ⁇ -dimethylformamide
  • a reduction reaction is performed.
  • the reducing agent used in the reduction reaction include metals (eg, iron, zinc, zinc amalgam, etc.) or salts of chromium compounds (eg, chromic chloride, chromic acetate, etc.) and organic or inorganic acids (eg, acetic acid) , Propionic acid, hydrochloric acid, etc.); catalytic reduction in the presence of a metal catalyst (eg, palladium carbon, Raney nickel, etc.).
  • Examples of the solvent used include alcohols (eg, methanol, ethanol), ethers (eg, tetrahydrofuran), esters (eg, ethyl acetate), and carboxylic acids (eg, acetic acid).
  • alcohols eg, methanol, ethanol
  • ethers eg, tetrahydrofuran
  • esters eg, ethyl acetate
  • carboxylic acids eg, acetic acid
  • a group R 2 ′ (R 21 represents a hydrocarbon group which may have a substituent.) Is introduced into the amino group by, for example, Bulletin de la Societe Chimique de France Part ie 2, 1970, Issue 5, 1901-1907 can be carried out by a method similar to or a method analogous thereto.
  • Compound (III) [Including compound (II). ] Can be used as a starting compound for producing the compound (I) of the present invention.
  • the salts of the starting compounds ( ⁇ ), (III) and the target compound (I) of the present invention are preferably pharmaceutically acceptable salts, for example, salts with inorganic bases, salts with organic bases, and salts with inorganic acids. Examples thereof include salts, salts with organic acids, salts with basic or acidic amino acids, and the like.
  • the salt with an inorganic base include, for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; and aluminum salts, ammonium salts and the like. Are listed.
  • Preferable examples of the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, ethanolamine, triethanolamine, dicyclohexylamine, ⁇ , ⁇ '-dibenzylethylenediamine And salts with amines.
  • Preferred examples of the salt with an inorganic acid include, for example, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
  • Suitable examples of salts with organic acids include, for example, formic acid, acetic acid, Examples include salts with trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like.
  • Preferred examples of the salt with a basic amino acid include, for example, salts with arginine, lysine, orditin and the like.
  • Preferred examples of the salt with an acidic amino acid include, for example, aspartic acid, dalsiminic acid, and the like. And salts thereof.
  • the prodrug of the compound (I) of the present invention is a compound that is converted into the compound (I) by a reaction with an enzyme, gastric acid, or the like under physiological conditions in a living body, that is, a compound that undergoes enzymatic oxidation, reduction, hydrolysis, or the like.
  • the compound (I) of the present invention when the compound (I) has an amino group as a substituent, the compound wherein the amino group is acylated, alkylated or phosphorylated; the compound (I) is substituted When the compound has a hydroxyl group, the hydroxyl group is acylated, alkylated, phosphorylated, or borated; when the compound (I) has a carboxyl group as a substituent, the propyloxyl group is esterified, And the like.
  • These compounds can be produced from compound (I) by a method known per se.
  • the prodrug of compound (I) can be obtained under physiological conditions as described in Hirokawa Shoten, 1990, “Development of Drugs,” Volume 7, Molecular Design, pp. 163 to 198. (I) may be changed.
  • the compound (I) of the present invention or a salt thereof has a strong osteogenesis promoting action, a cartilage formation promoting action, a cartilage destruction inhibitory action, and a chondrocyte differentiation induction promoting action, and is particularly stable, resorbable (in particular, It has excellent clinically useful properties such as oral absorbability and bioavailability. Moreover, its toxicity is low. Accordingly, the compound (I) or a salt thereof of the present invention can be used for various bone diseases in mammals (eg, humans, rats, mice, dogs, egrets, cats, dogs, bushus). , Osteoporosis, fracture, cartilage defect, rheumatoid arthritis involving cartilage, osteoarthritis involving cartilage Used for the prevention and treatment of arthritis.
  • mammals eg, humans, rats, mice, dogs, egrets, cats, dogs, bushus.
  • the compound (I) or a salt thereof of the present invention exhibits excellent alkaline phosphatase inducing activity, it has excellent bone formation promoting action and cartilage formation promoting action, and is useful for metabolic bone diseases including osteoporosis, It is useful as a preventive and therapeutic drug for osteochondral diseases.
  • the bone formation promoting agent and the cartilage formation promoting agent containing the compound (I) of the present invention or a salt thereof having such an action are used for bone fracture, refracture, bone defect, osteomalacia, bone fracture in the field of orthopedic surgery. Multiple myeloma It can be used as a bone tissue repair agent after surgery for lung cancer, breast cancer and the like.
  • applications can be expected in the treatment of periodontal disease, repair of periodontal tissue defects in periodontal disease, stabilization of artificial dental roots, repair of ridges and cleft palate.
  • the daily dose depends on the condition and weight of the patient, the method of administration and the like.
  • the amount of active ingredient [compound (I) of the present invention or a salt thereof] per adult (body weight: 50 kg) is about 1 to 300 mg, preferably about 1 to 30 mg.
  • the compound (I) of the present invention or a salt thereof can be used in combination with another bone resorption inhibitor or an osteogenesis promoter.
  • the concomitant drug include vitamin D 3 (eg, 1 ⁇ -hydroxyvitamin D 3 , 1,25-dihydroxyvitamin D 3 , flocalcitriol, Secarciferol, etc.), calcitonin (eg, ⁇ Nagi calcitonin, salmon calcitonin, bushu calcitonin, avicatonin, etc.), bisphosphonic acids (eg, etidronate, simadrone) Etc., sex hormone related compounds (eg, tibolone, estradiol, o saterone, raloxifene, droloxifene, olmeloxifene, tamoxifen, miefbristone, etc.), Ibriflavone, vitamin K 2 (eg, menatetrenone), sodium fluoride, parathyroid hormone ( ⁇ ⁇ )
  • the compound (I) of the present invention or a salt thereof is mixed with a pharmaceutically acceptable carrier, and solid preparations such as tablets, capsules, granules and powders; or liquid preparations such as syrups and injections, orally or It can be administered parenterally.
  • Transdermal preparations such as patches, cataplasms, ointments (including claims), plasters, tapes, lotions, solutions, suspensions, emulsions, and sprays can also be made.
  • Pharmaceutically acceptable carriers include various organic or inorganic carrier materials commonly used as pharmaceutical materials, such as excipients, lubricants, binders, and disintegrants in solid formulations; Formulated as auxiliaries, suspending agents, tonicity agents, buffers, soothing agents and the like. If necessary, pharmaceutical additives such as preservatives, antioxidants, stabilizers, coloring agents and sweeteners can be used.
  • excipients include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light caffeic anhydride and the like.
  • Preferred examples of the lubricant include, for example, magnesium stearate, calcium stearate, talc, colloid silica and the like.
  • binder examples include crystalline cellulose, arsenic starch, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like.
  • Preferred examples of the disintegrant include starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, low-substituted hydroxypropylcellulose, and the like.
  • Preferred examples of the solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like. -If necessary, oral preparations can be prepared by coating in a manner known per se for the purpose of taste masking, enteric coating or persistence.
  • the coating agent examples include hydroxypropylmethylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyoxyethylene glycol, Tween 80, bull-mouth nick F68, cell mouth, and phthalate. Hydroxypropyl methylcellulose phthalate, hydroxymethyl cellulose acetate succinate, Eudragit (manufactured by Rohm, Germany, methacrylic acid / acrylic acid copolymer) and the like are used.
  • solubilizer examples include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, and sodium citrate. And the like.
  • the suspending agent include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate;
  • surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate
  • examples include hydrophilic high molecular substances such as alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyshethylcellulose, and hydroxypropylcellulose.
  • the tonicity agent include sodium chloride, glycerin, D-mannitol and the like.
  • Preferred examples of the buffer include buffer solutions such as phosphate, acetate, carbonate, and citrate.
  • the soothing agent include benzyl alcohol and the like.
  • Preferable examples of the preservative include, for example, parabenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
  • Antioxidant Preferable examples thereof include, for example, sulfite, ascorbic acid and the like.
  • the compound (I) or a salt thereof of the present invention can be used not only as a preparation by the usual formulation technique as described above, but also as a sustained-release preparation by a sustained-release technique. As a method for producing a sustained-release preparation, for example, as described in Japanese Patent Application Laid-Open No.
  • aliphatic polyesters such as lactic acid-glycolic acid copolymer are dried in water and phase-separated. And a method of dispersing by a method such as a spray drying method. Sustained-release preparations obtained by these methods can be administered locally, for example, as a suspension of microcapsules or microspheres.
  • the compound (I) or a salt thereof of the present invention is preferably incorporated into a pharmaceutical composition together with polyethylene glycol as described in JP-A-10-338646.
  • compound (I) or a salt thereof is dispersed using an injectable hyaluronic acid preparation (eg, Kaken Pharmaceutical: Aru Injection) as a dispersion medium.
  • an injectable hyaluronic acid preparation eg, Kaken Pharmaceutical: Aru Injection
  • hyaluronic acid used in the dispersion medium non-toxic salts thereof may be used. Examples thereof include alkali metal salts such as sodium and potassium, and alkaline earth metal salts such as magnesium and calcium. Salts are preferably used.
  • Hyaluronic acid and non-toxic salts thereof have a molecular weight of about 200,000 to 500,000 (viscosity method), preferably about 500,000 to 300,000, and more preferably about 700,000 to 250,000. Is used.
  • the final concentration of hyaluronic acid or sodium hyaluronate in the dispersant is preferably less than 1% (w / v) as a viscosity, and is preferable in view of various operations, ease of administration, etc., and particularly about 0.02 to 1%. It is preferably less than about 0.1 to 1% (w / v).
  • the dispersion medium contains a pH regulator, a local anesthetic, an antibiotic, a solubilizer, an isotonic agent, an anti-adsorption agent, glycosaminoglycan, a polysaccharide, etc. by a method known per se. Is also good.
  • Preferred examples are mannitol, sorbitol, Examples include saline, glycine, ammonium acetate, or a water-soluble protein that can be injected into body fluids without exhibiting substantial pharmacological activity.
  • glycosaminodalican examples include hyaluronic acid, chondroitin, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, heparan sulfate, ketan sulfate and the like.
  • polysaccharide examples include an acidic polysaccharide such as arginic acid.
  • the water-soluble protein may be any protein that is soluble in water, physiological saline or a buffer, and includes, for example, human serum albumin, human serum globulin, collagen, and gelatin.
  • the content of the water-soluble protein is preferably from 0.05 to 50 mg, more preferably from 0.5 to 2 Omg, per one administration of the preparation. It is more preferably 0.75 to 1 O mg.
  • H regulator includes, for example, glycine, ammonium acetate, citric acid, hydrochloric acid, sodium hydroxide and the like.
  • Examples of the local anesthetic include chlorobutanol and xylocaine hydrochloride.
  • Examples of the above antibiotic include genyumycin.
  • Examples of the solubilizer include glycerin and polyethylene glycol 400.
  • Examples of the isotonic agent include mannitol, sorbitol, sodium chloride and the like.
  • Examples of the adsorption inhibitor include polyoxyethylene sorbitan monooleate.
  • the preparation may contain phosphoric acid or a salt thereof (for example, sodium phosphate, potassium phosphate, and the like).
  • phosphoric acid or a salt thereof for example, sodium phosphate, potassium phosphate, and the like.
  • concentration of sodium phosphate or potassium phosphate in the injection is about 0.1 mM to 50 mM, and about 0.1 mM to 100 mM. Is preferred.
  • 6-Hydroxy-8-methoxy-15-oxo-1,2,4,5-tetrahydro-13-benzocepin-12-carboxylic acid methyl ester (1.0 g), 2N aqueous potassium hydroxide solution (4 ml), THF (30 ml) was stirred at 70 ° C for 2 hours, acidified with dilute hydrochloric acid, and extracted with ethyl acetate. The extract was washed with aqueous ammonium chloride solution and saturated saline, dried (MgS04), and dried. The residual oil was crystallized from ethyl acetate and isopropyl ether to give 0.78 g (82%) of the title compound as brown crystals.
  • Example 22 1 Omg of the compound obtained in Example 4, After mixing 35mg of corn starch, 15Omg of corn starch, 2Omg of microcrystalline cellulose and 2.5mg of magnesium stearate, granulate. To this, 1 Omg of microcrystalline cellulose and 2.5 mg of magnesium stearate are added to the granules, mixed and pressed into tablets.
  • Example 22 1 Omg of the compound obtained in Example 4, After mixing 35mg of corn starch, 15Omg of corn starch, 2Omg of microcrystalline cellulose and 2.5mg of magnesium stearate, granulate. To this, 1 Omg of microcrystalline cellulose and 2.5 mg of magnesium stearate are added to the granules, mixed and pressed into tablets.
  • Example 22 1 Omg of the compound obtained in Example 4, After mixing 35mg of corn starch, 15Omg of corn starch, 2Omg of microcrystalline cellulose and 2.5mg of magnesium stearate, granulate. To this, 1 Omg of microcrystalline cellulose
  • Example 23 10 mg of the compound obtained in Example 11 ⁇ After mixing 35mg of corn starch, 15Omg of corn starch, 2Omg of microcrystalline cellulose and 2.5mg of magnesium stearate, granulate. To this, 1 Omg of microcrystalline cellulose and 2.5 mg of magnesium stearate are added to the granules, mixed and pressed into tablets. Test example 1
  • Alkaline phosphatase activity was measured as an indicator of bone formation using stromal cells prepared from bone marrow of normal rat femur.
  • the femoral bone marrow of a 7-week-old male Sprague-Dawley rat was used.
  • the stromal cells were prepared de Kisametazon to form mineralized bone-like tissue (1 0- 7 M) and) 3- glycerin port containing phosphoric acid (10- 2 M) ⁇ - M EM (minimum essential medium ) Cultured in liquid. After one week, the primary cells reached confluent, 0.
  • the compound of the present invention or a salt thereof has a strong bone formation promoting action, a cartilage formation promoting action, a cartilage destruction inhibitory action, a chondrocyte differentiation induction promoting action, and is stable and absorbable (particularly, oral absorption). Since it has excellent clinically useful properties such as bioavailability, it prevents bone and cartilage diseases such as osteoporosis, fractures, cartilage defects, rheumatoid arthritis involving cartilage, and osteoarthritis involving cartilage. It is also useful for treatment.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne des composés représentés par la formule générale (I) ou bien des sels de ceux-ci, lesquels présentent des effets accélérant l'ostéogenèse et la chondrogénèse et lesquels sont utiles en tant que médicaments; et des promédicaments ayant les deux effets, formule dans laquelle A représente un cycle benzène facultativement substitué; R1 représente un groupe hétérocyclique non aromatique facultativement substitué; R2 et R3 représentent chacun hydrogène ou hydrocarbyle facultativement substitué; et n représente un nombre entier de 0 à 3.
PCT/JP1999/004269 1998-08-07 1999-08-06 Derives de benzothiepine, leur procede de preparation et leurs utilisations Ceased WO2000008018A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU51949/99A AU5194999A (en) 1998-08-07 1999-08-06 Benzothiepin derivatives, process for the preparation of the same and uses thereof
EP99936994A EP1103552A4 (fr) 1998-08-07 1999-08-06 Derives de benzothiepine, leur procede de preparation et leurs utilisations
US09/744,857 US6355672B1 (en) 1998-08-07 1999-08-06 Benzothiepin derivatives, process for the preparation of the same and uses thereof
CA002339662A CA2339662A1 (fr) 1998-08-07 1999-08-06 Derives de benzothiepine, leur procede de preparation et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10/225065 1998-08-07
JP22506598 1998-08-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/744,857 A-371-Of-International US6355672B1 (en) 1998-07-08 1999-08-06 Benzothiepin derivatives, process for the preparation of the same and uses thereof
US10/044,787 Division US6531604B2 (en) 1998-07-08 2002-01-11 Benzothiepine derivatives, their production and use

Publications (1)

Publication Number Publication Date
WO2000008018A1 true WO2000008018A1 (fr) 2000-02-17

Family

ID=16823496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/004269 Ceased WO2000008018A1 (fr) 1998-08-07 1999-08-06 Derives de benzothiepine, leur procede de preparation et leurs utilisations

Country Status (5)

Country Link
US (2) US6355672B1 (fr)
EP (1) EP1103552A4 (fr)
AU (1) AU5194999A (fr)
CA (1) CA2339662A1 (fr)
WO (1) WO2000008018A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
HK1052183A1 (zh) * 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JPWO2003024930A1 (ja) * 2001-09-10 2004-12-24 メルシャン株式会社 ピペコリン酸アミド誘導体の製造方法
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
BR0213501A (pt) * 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
JP2003187146A (ja) * 2001-12-17 2003-07-04 Matsushita Electric Ind Co Ltd データ提供サービスシステム
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
EP1640010A1 (fr) * 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent d'induction de croissance dans la masse osseuse
EP1849465A4 (fr) * 2005-02-18 2008-12-24 Takeda Pharmaceutical Agent de controle de la fonction du recepteur gpr34
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
DK3400944T3 (da) 2010-11-04 2020-10-12 Albireo Ab Ibat-inhibitorer til behandling af leversygdomme
EP3278796A1 (fr) 2011-10-28 2018-02-07 Lumena Pharmaceuticals LLC Inhibiteurs du recyclage de l'acide biliaire pour traitement de l'hypercholémie et de la maladie cholestatique hépatique
EP3266457A1 (fr) 2011-10-28 2018-01-10 Lumena Pharmaceuticals LLC Inhibiteurs du recyclage de l'acide biliaire pour le traitement de maladies cholestatiques hépatiques pédiatriques
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (fr) 2014-10-24 2016-04-27 Ferring BV Formes crystallines d'Elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112312893A (zh) 2018-06-20 2021-02-02 阿尔比里奥公司 奥德昔巴特的药物制剂
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
ES2937153T3 (es) 2019-02-06 2023-03-24 Albireo Ab Compuestos de benzotiadiazepinas y su uso como moduladores de ácidos biliares
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
FI4069360T3 (fi) 2019-12-04 2024-02-20 Albireo Ab Bentsotia(di)atsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina
JP7748451B2 (ja) 2020-08-03 2025-10-02 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3196488A1 (fr) 2020-11-12 2022-05-19 Albireo Ab Odevixibat pour le traitement de la cholestase intrahepatique familiale progressive (cifp)
CA3198216A1 (fr) 2020-12-04 2022-06-09 Albireo Ab Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03232880A (ja) * 1988-12-28 1991-10-16 Takeda Chem Ind Ltd 含硫黄複素環化合物
JPH04364179A (ja) * 1990-05-30 1992-12-16 Takeda Chem Ind Ltd 含硫黄複素環化合物
JPH08231569A (ja) * 1994-12-28 1996-09-10 Takeda Chem Ind Ltd 光学活性ベンゾチエピン誘導体、その製造法および剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD98094A1 (fr) * 1972-06-19 1973-06-12
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
WO1989008652A1 (fr) * 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiazolidinedione comme agents hypoglycemiques
US5158943A (en) 1988-11-21 1992-10-27 Takeda Chemical Industries, Ltd. Sulfur-containing heterocyclic compounds
WO1993020073A1 (fr) * 1992-04-07 1993-10-14 Pfizer Inc. Derives d'indole en tant qu'agonistes de 5-ht1
FI952804A7 (fi) 1992-12-11 1995-06-07 Ciba Geigy Ag Substituoidut bentsatsepinonit
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
TW403757B (en) 1994-12-28 2000-09-01 Takeda Chemical Industries Ltd Optically active benzothiepin derivative, its preparation and use
HUP9802573A3 (en) 1995-06-05 2000-04-28 Takeda Chemical Industries Ltd Osteogenetic promoting pharmaceutical composition containing benzothian or benzothiepane derivatives and a biodegradable polimer
CA2226317A1 (fr) 1995-07-24 1997-02-06 Takeda Chemical Industries, Ltd. Production de sels de benzothiepine a activite optique
ATE221520T1 (de) * 1995-09-29 2002-08-15 Glaxo Wellcome Spa Tetrahydrochinoline als nmda antagonisten
AU2231397A (en) * 1996-03-08 1997-09-22 Torii Pharmaceutical Co., Ltd. Thiazolidine-2,4-dione derivatives
DE69716469T2 (de) 1996-08-26 2003-02-20 Takeda Chemical Industries, Ltd. Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
FR2764889B1 (fr) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6043254A (en) * 1998-04-03 2000-03-28 Boehringer Ingelheim Pharma Kg Indolinones having kinase-inhibiting activity
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2334815A1 (fr) 1998-06-15 1999-12-23 Haruhiko Makino Composition traitant une maladie du cartilage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03232880A (ja) * 1988-12-28 1991-10-16 Takeda Chem Ind Ltd 含硫黄複素環化合物
JPH04364179A (ja) * 1990-05-30 1992-12-16 Takeda Chem Ind Ltd 含硫黄複素環化合物
JPH08231569A (ja) * 1994-12-28 1996-09-10 Takeda Chem Ind Ltd 光学活性ベンゾチエピン誘導体、その製造法および剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1103552A4 *

Also Published As

Publication number Publication date
US6531604B2 (en) 2003-03-11
US20020128308A1 (en) 2002-09-12
EP1103552A1 (fr) 2001-05-30
US6355672B1 (en) 2002-03-12
AU5194999A (en) 2000-02-28
CA2339662A1 (fr) 2000-02-17
EP1103552A4 (fr) 2003-01-15

Similar Documents

Publication Publication Date Title
WO2000008018A1 (fr) Derives de benzothiepine, leur procede de preparation et leurs utilisations
US6346521B1 (en) Optically active 2R, 4S benzothiepin isomer
JP2992653B2 (ja) 含硫黄複素環化合物
KR20070034635A (ko) 치환 히단토인
JPWO2005103012A1 (ja) ヒドラジノ複素環ニトリル化合物およびその用途
AU2014353006B2 (en) Quinazoline derivatives as TAM family kinase inhibitors
JP2920385B2 (ja) １，２，５‐ベンゾチアジアゼピン誘導体，その製造法および用途
US6552054B1 (en) Chromone derivatives, process for the preparation of the same and uses thereof
PT1641787E (pt) Dicetopiperazinas substituídas e sua utilização como antagonistas da oxitocina
HUP0300028A2 (en) Thienopyridine derivatives, their production and use and pharmaceutical compositions containing them
KR101615114B1 (ko) 신규한 벤조티오펜 옥시드 유도체 또는 그의 염
JP3165866B2 (ja) 含硫黄複素環化合物
JP2000109480A (ja) ベンゾチエピン誘導体、その製造法および用途
JP2008515777A (ja) 疾患治療用のヒストンデアセチラーゼ阻害剤としての新規スルホンアミド
JP2008515777A5 (fr)
JPWO2000008018A1 (ja) ベンゾチエピン誘導体、その製造法および用途
JP2724396B2 (ja) 骨粗鬆症予防治療剤
RU2041875C1 (ru) Серусодержащие гетероциклические соединения или их фармацевтически приемлемые соли и состав, обладающий ингибирующим действием на костную резорбацию
JP3232350B2 (ja) 縮環したチアジアゾール誘導体、その製造法および用途
JP2946298B2 (ja) 光学活性ベンゾチエピン誘導体、その製造法および剤
JP2001139571A (ja) クロモン誘導体、その製造法及び用途
JP2000198780A (ja) 含酸素複素環化合物、その製造法及び用途
JPWO2001016127A1 (ja) クロモン誘導体、その製造法及び用途
JPH09183784A (ja) 光学活性ベンゾチエピン誘導体、その製造法および剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09744857

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2339662

Country of ref document: CA

Ref country code: CA

Ref document number: 2339662

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999936994

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999936994

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 2000563651

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1999936994

Country of ref document: EP